Immunic to participate in scientific and investor conferences in july

New york , june 29, 2023 /prnewswire/ --  immunic, inc.  (nasdaq: imux), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following scientific and investor conferences in july: july 6-8: symposium 234: mucosal immunology – a translational view into the clinic. martina wirth, ph.d.
IMUX Ratings Summary
IMUX Quant Ranking